Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses

P. Ferolla, A. Faggiano, F. Grimaldi, D. Ferone, G. Scarpelli, V. Ramundo, R. Severino, M. C. Bellucci, L. M. Camera, G. Lombardi, G. Angeletti, A. Colao

Research output: Contribution to journalArticle

Abstract

Background: In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited anti-proliferative effects. Aim: The objective of this study was to evaluate a different schedule of LAR treatment consistent with a shorter interval between administrations (21 days) in WD-NET patients with progressive disease at standard-dose interval. Subjects and methods: Twenty-eight patients followed for diagnosis and therapy of WDNET who had tumor progression during therapy with LAR 30 mg every 28 days were enrolled. Clinical, biological, and objective tumor response was evaluated after LAR 30 mg every 21 days. Time to progression was also evaluated after LAR 30 mg every 21 days and compared to LAR 30 mg every 28 days. Results: The treatment with LAR 30 mg every 21 days resulted in complete and partial control of clinical symptoms in 40% and 60% of cases, respectively. Circulating neuroendocrine markers were significantly decreased in 30% of cases. A stabilization of disease was obtained in 93% and objective response in 7%. The median time to progression was significantly longer by using the shortened interval of LAR administration as compared to the standard one (30 vs 9 months, p

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalJournal of Endocrinological Investigation
Volume35
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Neuroendocrine Carcinoma
Octreotide
Neuroendocrine Tumors
Therapeutics
Neoplasms
Appointments and Schedules

Keywords

  • High doses
  • Neuroendocrine tumor
  • Octreotide LAR therapy
  • Progressive disease
  • Somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. / Ferolla, P.; Faggiano, A.; Grimaldi, F.; Ferone, D.; Scarpelli, G.; Ramundo, V.; Severino, R.; Bellucci, M. C.; Camera, L. M.; Lombardi, G.; Angeletti, G.; Colao, A.

In: Journal of Endocrinological Investigation, Vol. 35, No. 3, 03.2012, p. 326-331.

Research output: Contribution to journalArticle

Ferolla, P, Faggiano, A, Grimaldi, F, Ferone, D, Scarpelli, G, Ramundo, V, Severino, R, Bellucci, MC, Camera, LM, Lombardi, G, Angeletti, G & Colao, A 2012, 'Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses', Journal of Endocrinological Investigation, vol. 35, no. 3, pp. 326-331. https://doi.org/10.3275/7869
Ferolla, P. ; Faggiano, A. ; Grimaldi, F. ; Ferone, D. ; Scarpelli, G. ; Ramundo, V. ; Severino, R. ; Bellucci, M. C. ; Camera, L. M. ; Lombardi, G. ; Angeletti, G. ; Colao, A. / Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. In: Journal of Endocrinological Investigation. 2012 ; Vol. 35, No. 3. pp. 326-331.
@article{61a150f2a2cb4ca18483a79d9fc166b9,
title = "Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses",
abstract = "Background: In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited anti-proliferative effects. Aim: The objective of this study was to evaluate a different schedule of LAR treatment consistent with a shorter interval between administrations (21 days) in WD-NET patients with progressive disease at standard-dose interval. Subjects and methods: Twenty-eight patients followed for diagnosis and therapy of WDNET who had tumor progression during therapy with LAR 30 mg every 28 days were enrolled. Clinical, biological, and objective tumor response was evaluated after LAR 30 mg every 21 days. Time to progression was also evaluated after LAR 30 mg every 21 days and compared to LAR 30 mg every 28 days. Results: The treatment with LAR 30 mg every 21 days resulted in complete and partial control of clinical symptoms in 40{\%} and 60{\%} of cases, respectively. Circulating neuroendocrine markers were significantly decreased in 30{\%} of cases. A stabilization of disease was obtained in 93{\%} and objective response in 7{\%}. The median time to progression was significantly longer by using the shortened interval of LAR administration as compared to the standard one (30 vs 9 months, p",
keywords = "High doses, Neuroendocrine tumor, Octreotide LAR therapy, Progressive disease, Somatostatin analogues",
author = "P. Ferolla and A. Faggiano and F. Grimaldi and D. Ferone and G. Scarpelli and V. Ramundo and R. Severino and Bellucci, {M. C.} and Camera, {L. M.} and G. Lombardi and G. Angeletti and A. Colao",
year = "2012",
month = "3",
doi = "10.3275/7869",
language = "English",
volume = "35",
pages = "326--331",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses

AU - Ferolla, P.

AU - Faggiano, A.

AU - Grimaldi, F.

AU - Ferone, D.

AU - Scarpelli, G.

AU - Ramundo, V.

AU - Severino, R.

AU - Bellucci, M. C.

AU - Camera, L. M.

AU - Lombardi, G.

AU - Angeletti, G.

AU - Colao, A.

PY - 2012/3

Y1 - 2012/3

N2 - Background: In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited anti-proliferative effects. Aim: The objective of this study was to evaluate a different schedule of LAR treatment consistent with a shorter interval between administrations (21 days) in WD-NET patients with progressive disease at standard-dose interval. Subjects and methods: Twenty-eight patients followed for diagnosis and therapy of WDNET who had tumor progression during therapy with LAR 30 mg every 28 days were enrolled. Clinical, biological, and objective tumor response was evaluated after LAR 30 mg every 21 days. Time to progression was also evaluated after LAR 30 mg every 21 days and compared to LAR 30 mg every 28 days. Results: The treatment with LAR 30 mg every 21 days resulted in complete and partial control of clinical symptoms in 40% and 60% of cases, respectively. Circulating neuroendocrine markers were significantly decreased in 30% of cases. A stabilization of disease was obtained in 93% and objective response in 7%. The median time to progression was significantly longer by using the shortened interval of LAR administration as compared to the standard one (30 vs 9 months, p

AB - Background: In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited anti-proliferative effects. Aim: The objective of this study was to evaluate a different schedule of LAR treatment consistent with a shorter interval between administrations (21 days) in WD-NET patients with progressive disease at standard-dose interval. Subjects and methods: Twenty-eight patients followed for diagnosis and therapy of WDNET who had tumor progression during therapy with LAR 30 mg every 28 days were enrolled. Clinical, biological, and objective tumor response was evaluated after LAR 30 mg every 21 days. Time to progression was also evaluated after LAR 30 mg every 21 days and compared to LAR 30 mg every 28 days. Results: The treatment with LAR 30 mg every 21 days resulted in complete and partial control of clinical symptoms in 40% and 60% of cases, respectively. Circulating neuroendocrine markers were significantly decreased in 30% of cases. A stabilization of disease was obtained in 93% and objective response in 7%. The median time to progression was significantly longer by using the shortened interval of LAR administration as compared to the standard one (30 vs 9 months, p

KW - High doses

KW - Neuroendocrine tumor

KW - Octreotide LAR therapy

KW - Progressive disease

KW - Somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=84862889164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862889164&partnerID=8YFLogxK

U2 - 10.3275/7869

DO - 10.3275/7869

M3 - Article

C2 - 21757992

AN - SCOPUS:84862889164

VL - 35

SP - 326

EP - 331

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 3

ER -